All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Join our

Treatment sequencing for anemic myelofibrosis

with Jean-Jacques Kiladjian & Angela Fleischman

Monday, February 26, 2024 | 16:30 CET

This independent educational activity is supported by Bristol Myers Squibb. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.

  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-01-05T12:02:37.000Z

Can ruxolitinib replace hydroxyurea as a frontline therapy for polycythemia vera?

Jan 5, 2024
Share:
Learning objective: After reading this, learners will be able to cite a new clinical development in polycythemia vera.

Bookmark this article

During the International Academy for Clinical Hematology (IACH) 2023 Congress, the MPN Hub spoke with Claire Harrison, Guy's and St Thomas' NHS Foundation Trust, London, UK. We asked, Can ruxolitinib replace hydroxyurea as a frontline therapy for polycythemia vera? 

Harrison begins by reflecting on current frontline treatment options for patients with polycythemia vera and mentions the introduction of ruxolitinib as a second-line treatment choice. She then discusses whether treatment with a drug is always an appropriate frontline option, outlining clinical scenarios when this should be strongly considered. Harrison continues by evaluating the choice of ruxolitinib or hydroxyurea, specifically in high-risk patients. Finally, she highlights important points from the recent phase II MAJIC-PV study (ISRCTN61925716).

Can ruxolitinib replace hydroxyurea as a frontline therapy for PV?

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox